PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-51.43%
Negative net income growth while CRVO stands at 7.43%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
31.39%
D&A growth of 31.39% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
0.95%
SBC growth of 0.95% while CRVO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
2999.17%
Well above CRVO's 86.55% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
284.36%
A yoy AP increase while CRVO is negative at -1666.15%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
139.25%
Growth well above CRVO's 176.20%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
3478.66%
Well above CRVO's 190.58%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
582.93%
Operating cash flow growth above 1.5x CRVO's 15.28%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-3757.14%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3757.14%
We reduce yoy invests while CRVO stands at 100.44%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-4.55%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.